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Tumor cells frequently undergo metabolic reprogramming, but it is unknown how these metabolic changes
relate to drug resistance. A recent article now demonstrates that PI3K/AKT signaling causes a metabolic
switch from glutaminolysis to aerobic glycolysis in Notch-dependent T cell acute lymphoblastic leukemia
(T-ALL).Metabolic reprogramming of cancer cells
has recently entered the pantheon of
‘‘cancer hallmarks,’’ core characteristics
that all cancer cells share. Arguably, the
best characterized of these metabolic
changes is the Warburg effect, the ten-
dency for cancer cells to rely on glycolysis
for energy and anabolic metabolism, even
when oxygen levels are adequate for
oxidative phosphorylation (Ward and
Thompson, 2012). This seemingly para-
doxical use of fuel is readily understood
when one considers that cell growth de-
pends on the biosynthesis of cellular
building blocks frommetabolic intermedi-
ates, which are largely provided by the
glycolytic and tricarboxylic acid (TCA)
pathways. In cancers and rapidly growing
normal tissues, these pathways are
primed by increased cellular uptake of
glucose and glutamine, a ‘‘hunger’’ that
can be visualized clinically using positron
emission tomography (PET) scanning.
It is now appreciated that many onco-
genic stimuli impinge on metabolic cir-
cuits that promote Warburg metabolism.
Among these is the Notch pathway, which
is upregulated in the majority of human
T-ALLs (T cell acute lymphoblastic leuke-
mia), usually by activating mutations in
NOTCH1 (Weng et al., 2004). Recent
work from Herranz et al. (2015) lays out
in new detail how Notch influences inter-
mediary metabolism in T-ALL cells. Using
murine models and xenografted primary
human T-ALL (so-called primagrafts), the
authors show that T-ALLs with activating
mutations of NOTCH1 use glutamine as
the dominant source of intermediates for
priming the TCA cycle (a process referred
to as anapleurosis). Glutamine usage de-creases dramatically following pharma-
cologic inhibition or genetic ablation of
Notch signaling, whereas expression of
enzymes that augment glutaminolysis
(e.g., the M2 isoform of pyruvate kinase
PKM2 and glutaminase [GLS]) rescues
lymphoblasts from Notch inhibition.
Furthermore, Herranz et al. (2015) show
that combining Notch and glutaminolysis
inhibitors is an effective treatment in
mice bearing T-ALL primagrafts, vali-
dating therapeutic strategies focused on
targeting pathways that enable Warburg
metabolism in this disease.
The link between Notch and glutamine
metabolism in T-ALL is in line with prior
work showing that a critical downstream
target of NOTCH1 in this cellular context
is MYC (Palomero et al., 2006; Weng
et al., 2006), a key regulator of glutaminol-
ysis. The importance of the Notch/MYC
signaling axis is supported by observa-
tions showing that mice engineered to
express MYC in T cell progenitors
develop T-ALLs that are Notch indepen-
dent and that T-ALL cells that are ad-
dicted to conditional MYC transgenes
can be rescued from withdrawal of trans-
genic MYC by Notch via upregulation of
the endogenous MYC locus (Weng et al.,
2006). MYC remains a difficult protein to
target directly, but the Notch pathway is
amenable to targeting with small mole-
cules (gamma-secretase inhibitors) as
well as blocking antibodies, both of which
are being tested in clinical trials. This
would seem to offer an ideal opportunity
for development of a rational targeted
therapy, but results to date have been
underwhelming; while most patients with
T-ALL show a decrease in lymphoblastCell Metabolism 22,counts with Notch inhibitor treatment,
only a small minority (perhaps 5%–10%)
of those with NOTCH1-mutated T-ALL
achieve major hematologic responses.
A central translational question in the field
that emerges from this experience is one
that is simple to state but complex to
answer: how do T-ALL cells escape from
Notch dependency?
Herranz et al. (2015) suggest two pos-
sibilities, both involving metabolic adap-
tations. It has long been recognized that
the withdrawal of Notch from human
T-ALL cells results in a decrease in cell
size and cell-cycle arrest (Weng et al.,
2004), but little cell death, changes that
are accompanied by induction of auto-
phagy. Herranz et al. demonstrate that
Notch inhibitor-treated leukemia cells
show features of autophagy and further
extend this observation by showing that
T-ALL cells with defects in autophagy
due to loss of atg7 are more responsive
to Notch inhibitors (Herranz et al., 2015).
Thus, autophagy appears to help Notch-
addicted T lymphoblasts survive in the
face of Notch inhibition and nutrient re-
striction. Other Notch-mutated T-ALLs
(and some cell lines), however, are known
to continue to grow unabated in the face
of Notch inhibition. Herranz et al. (2015)
provide compelling data indicating that
one mode of metabolic escape involves
upregulation of PI3K/AKT signaling and
increased dependence on glycolysis
(instead of glutaminolysis) for anapleuro-
sis. In the models that Herranz et al.
(2015) employed, upregulation of PI3K/
AKT signaling was achieved through loss
of the tumor suppressor gene PTEN,
which encodes a lipid phosphatase thatNovember 3, 2015 ª2015 Elsevier Inc. 759
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Previewsacts as a brake on PI3K/AKT signaling.
PTEN loss-of-function mutations are
found in approximately 20% of human
T-ALL (Palomero et al., 2007), and
Herranz et al. (2015) note that PTEN is
also downregulated in lymphoblasts
following Notch withdrawal through un-
certain mechanisms. Loss of PTEN func-
tion was associated with changes in the
expression of genes that enable utilization
of glycolysis. Of potential relevance,
PI3K/AKT signaling can also augment
MYC function by enhancing translation
of MYC mRNA and other mechanisms
(Stine et al., 2015). Together, this ‘‘rewir-
ing’’ of signaling inputs and metabolic
outputs appears to relieve cells of their
dependency on Notch, providing a
plausible (but still untested) explanation
for the failure of Notch inhibitors to
achieve deep and sustained responses
in patients.
Work from our own group suggests that
heterogeneity in the Notch/MYC signaling
axis and cellular metabolic circuits may
exist in T-ALL even prior to exposure to
Notch inhibitors (Knoechel et al., 2014).
This is in line with work in other tumor
types, in which certain cells rely more on
Warburg metabolism or oxidative phos-760 Cell Metabolism 22, November 3, 2015 ªphorylation. This variability has in part
been attributed to deprivation from oxy-
gen and nutrients in solid tumors where
central necrosis and poor vascularization
frequently occur, but such anatomic
factors are not as clearly involved in
leukemias, which reside in the bone
marrow and have ready access to the
vasculature. The studies of Herranz et al.
(2015) suggest ways to co-target different
metabolic states in T-ALL, for example
by combining Notch inhibitors with
PI3K/AKT inhibitors. Notably, the Notch/
MYC signaling axis also appears to be
present in other Notch-addicted tumors,
such as breast cancers and certain B
cell neoplasms (Stoeck et al., 2014). The
principles described here may therefore
have broad implications for the use of
targeted agents against Notch. It will
be of interest to see if similar metabolic
shifts occur with Notch inhibition in
malignanices other than T-ALL and if so
if these are also dependent on PI3K/AKT
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